How LeapSpace expands publisher-neutral scientific content for Corporate R&D decisions
More evidence for cross-disciplinary R&D decisions
Corporate R&D decisions rarely stay within one discipline. Product, clinical, safety, manufacturing and engineering questions can depend on evidence across fields, sources and publishers. LeapSpace gives teams a broader, publisher-neutral evidence base within a research-grade AI workspace, helping them find relevant evidence, inspect the source path and decide what merits closer review.
What the content expansion adds
A response is only the starting point for Corporate R&D. LeapSpace helps teams achieve better outcomes across their complete workflow, while supporting critical thinking, igniting curiosity and keeping experts in control. It is grounded in the world’s most comprehensive and trusted collection of up-to-date peer-reviewed science available to any AI research tool. Alongside 2.6 billion cited references from Scopus abstracts, LeapSpace is now also powered by full-text content that accounts for 56% of all recent global research citations and 42% of all global research articles published since 2021.¹
¹ Elsevier analysis using Scopus, June 2026.
A broader, publisher-neutral evidence foundation
The content expansion is driven by new content licensing partnerships with BMJ Group,opens in new tab/window Rockefeller University Pressopens in new tab/window, and American Society of Civil Engineersopens in new tab/window, along with agreements for selected full-text content from existing content licensing partners including Emerald Publishingopens in new tab/window, IOP Publishingopens in new tab/window, and Sage Publishingopens in new tab/window, and more than 1,500 additional scholarly publishers and societies. LeapSpace includes Elsevier’s full-text peer-reviewed articles and books, plus 100+ million scientific records from Scopus covering content from 7,000+ publishers. Together, these provide researchers with a cross-publisher content foundation that spans the leading journals and societies across science.
For more detail on how selected full-text content is indexed and displayed, and how references link back to the publisher platform, visit the LeapSpace Content Partners page. Availability depends on the selected content, licensing arrangements and the user’s access rights.
Content at a glance
Full text 20M+ versions of record indexed in Scopus – mostly published after 2000 | Abstracts and metadata The Scopus corpus of 107+ million interconnected records | Funding opportunities International and local awards |
|---|---|---|
Elsevier: - 12 M articles (including from society-owned journals), book series, handbooks and major reference works - ~1.1 million book chapters Non-Elsevier: - ~10M+ OA (CC-BY) and subscription journal article agreements | - 29,972+ active journals - 493,729+ books - 28.6+ M OA items - 7,000+ publishers - 25.4+ M author profiles - 94,000+ organization profiles Data elements used include abstracts, titles, author and indexed keywords, total reference counts and cited-by counts. | - 40,000+ active and recurring funding opportunities, with strongest coverage in North America, the UK, Australia, and the EU. - $100+ B (USD) worth of active funding opportunities - 16,000+ government and private funding organizations |
Data correct as of August 2026. New content is added daily. Retracted articles are excluded, where identified.
Why breadth matters for Corporate R&D
Corporate R&D questions rarely stay within one discipline. A life sciences decision may connect mechanism, translational models, efficacy, safety, clinical endpoints and device evidence. An engineering decision may connect materials, process conditions, performance, reliability, manufacturing and scale-up. LeapSpace provides a broader, publisher-neutral starting point for examining those connections. It does not resolve the decision; it gives experts a wider evidence set, a visible source path and clearer signals about where evidence is thin, mixed or absent.
The workflow stays inspectable
LeapSpace supports the tasks research teams need to complete effectively. Search or Deep Research helps teams discover and synthesize evidence. Reference Details and linked passages show what a cited source says. Claim Radar tests a claim against the wider literature. Compare Tables organizes papers in a customizable table to help you identify key contents and decide what to read next. Writing Coach helps strengthen the rationale, while the user decides what suggested changes, if any, to accept. Watch the full workflow LeapSpace Demo then run it yourself in LeapSpaceopens in new tab/window.
Governance for transparency and publisher neutrality
Alongside the content expansion, Elsevier has established an independent Advisory Board to provide expert guidance on the algorithms that surface and evaluate content, publisher-neutral content discovery and search ranking, responsible AI use in research, and transparent, explainable outputs. This is governance context rather than a product feature: the Board does not certify individual claims or replace expert review.
For further detail on the Advisory Board, its members and its role in supporting transparency, publisher neutrality and responsible AI in LeapSpace, visit LeapSpace Advisory Board: Independent Oversight for AI Search.
A more inspectable path
For Corporate R&D, broader content is useful when it improves the quality of the question and the defensibility of the response. LeapSpace is designed to support the work between discovery and decision: explore the landscape, inspect the evidence and decide what merits closer reading.
Frequently asked questions
LeapSpace generates responses using peer-reviewed full-text content from Elsevier and selected full-text content from content partners, alongside Scopus abstracts and metadata.
LeapSpace indexes content made available under licensing agreements. A named content partner’s entire portfolio is not necessarily included. Availability depends on the selected content and licensing arrangements.
No. A third-party publisher subscription is not required to use LeapSpace. LeapSpace can still use selected content-partner full-text content to generate responses.
Full-text access remains on the publisher’s platform. When partner content is referenced, LeapSpace displays a contextual snippet and links to the full article. Reading or downloading it requires the appropriate entitlement or subscription. LeapSpace does not grant or determine access to the publisher’s platform.
No. Scopus abstracts and metadata support broader research discovery. They are not equivalent to full-text access.
LeapSpace’s ranking methodology is certified as publisher-neutral, with no preferential treatment or black-box behavior. Content is surfaced based on relevance to the research task.
Visit the LeapSpace Content Partners page. The page explains how partner content is indexed, displayed and linked to the publisher platform. More content partners may be announced in the coming months.
No. The Advisory Board provides expert guidance on algorithms, transparency, publisher-neutral content standards, responsible AI and explainable outputs. It does not certify individual claims or replace expert review.
